Cortice Announces Enrollment of a Phase 2 Trial Evaluating TPI 287 Plus Avastin(R) for Treatment of Recurrent Glioblastoma Naive to Prior Anti-Angiogenic Therapy
January 09, 2014 10:00 ET
|
Cortice Biosciences
NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, Inc. announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and...
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
January 07, 2014 09:00 ET
|
Cortice Biosciences
NEW YORK, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, a biotechnology company developing novel agents for the treatment of oncologic and neurologic indications, announced today the...